Migraines with and without aura and their response to preventive therapy with topiramate.
Author(s): Reuter U, Del Rio MS, Diener HC, Allais G, Davies B, Gendolla A, Pfeil J, Schwalen S, Schauble B, van Oene J
Affiliation(s): Department of Neurology, Charite Universitatsmedizin, Berlin, Germany. firstname.lastname@example.org
Publication date & source: 2010-05, Cephalalgia., 30(5):543-51. Epub 2010 Feb 11.
Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Data from the Prolonged Migraine Prevention (PROMPT) with Topiramate trial were evaluated post hoc to determine whether topiramate could prevent migraine auras, and whether its efficacy in preventing migraine headaches was similar in patients with (MA; n = 269) and without (MoA; n = 542) aura. Migraines and auras were recorded during prospective baseline, 6-month open-label (OL) topiramate and 6-month double-blind (DB), placebo-controlled phases. In the last 28 OL days, migraines without aura and migraine auras decreased by 43.1% and 54.1%, respectively, in MA patients. MoA patients experienced a 44.3% reduction in migraines. In the DB phase, increases in migraines with placebo vs. topiramate were similar to the full study, but were generally not statistically significant, probably due to lack of power in the subgroup analysis. Similarly, there were no statistically significant changes in number of auras between groups. Thus, topiramate appears to reduce migraine auras in parallel with headache reductions, which are similar in patients with and without aura.